THE TRENDLINES GRP SP/ADR - TRNLY STOCK NEWS

CoreBone, based in Tel Aviv, Israel, has announced a successful investment round, raising $3.7 million. The investment includes $3 million from the Guangzhou Sino-Israel Biotech Investment Fund for its Chinese subsidiary, alongside $700,000 from The Trendlines Group and Agriline. This funding will facilitate the expansion of CoreBone's bioactive, coral-based bone graft materials into the rapidly growing Chinese market, which bans the import of foreign human-derived grafts, thus presenting a unique opportunity for CoreBone's products.

The Trendlines Group (OTCQX: TRNLY) will present at the Lytham Partners Fall 2021 Investor Conference on October 5, 2021, from 8:45-9:15 AM ET. A webcast of the presentation will be available live and archived on Trendlines' website.

Management will also hold virtual one-on-one meetings during the conference from October 5-7. Interested parties can contact Lytham Partners to arrange meetings.

MetoMotion, a developer of intelligent robotic systems for agriculture, has secured a $5 million investment led by Ridder and Navus Ventures. The funding will finalize R&D efforts, set up production, and launch commercial products aimed at addressing labor shortages in greenhouse farming. The GRoW robot utilizes AI for harvesting and improves crop management through data collection. This partnership enhances MetoMotion's capabilities and aims to revolutionize greenhouse operations by automating labor-intensive tasks, ultimately reducing production costs and improving yields.

AgroScout has successfully completed a $7.5 million Series A funding round to enhance its AI cloud platform for remote agronomy. This initiative aims to serve the 500 million largely unserved farms globally, enabling sustainable crop protection and carbon accountability. The investment was led by Kibbutz Yotvata, alongside other investors including Agriline and The Trendlines Group. AgroScout's platform offers actionable insights for crop management, decreases pesticide usage, and supports early pest detection to improve yields. The company focuses on affordable, efficient farming solutions for growers.

Vessi Medical has completed its first-in-human procedure using its cryoablation solution for non-muscle invasive bladder cancer (NMIBC) at Rambam Healthcare Campus, Israel. The procedure was successful, demonstrating ease of use and no complications, with the patient reporting no pain post-discharge. This marks a significant step towards regulatory approval for Vessi's minimally invasive treatment, which aims to improve patient quality of life compared to traditional surgical options.

ZygoFix has received the CE mark for its innovative zLOCK Spinal Fusion System designed for chronic back pain treatment. This minimally invasive system utilizes a screwless design, enhancing safety and reducing surgical invasiveness with only two incisions needed compared to traditional methods. The zLOCK system has been in clinical use in Hungary and Israel for over three years, demonstrating high satisfaction among patients and physicians. ZygoFix also secured ISO13485 certification and plans to conduct a pivotal study in the EU to gather more clinical data.

IBI-Ag, a biotechnology firm in Israel, successfully closed an investment round aimed at optimizing its bioinsecticide products and expanding its portfolio. Key investors include the Bayer-Trendlines Ag Innovation Fund and Agriline, with additional support from the Israel Innovation Authority. IBI-Ag's innovative bioinsecticides utilize single domain antibodies for effective insect control while minimizing environmental impact. The global demand for sustainable agricultural solutions highlights the relevance of IBI-Ag's technology in addressing crop pest issues that result in significant economic losses.

Omeq Medical has appointed Carl Rickenbaugh as the chair of its board of directors. Rickenbaugh, with extensive experience in the medical device sector, aims to lead Omeq's strategic direction toward commercialization of its innovative epidural delivery technology. The company’s device enhances the accuracy of epidural injections, a procedure used in over 40 million cases annually, addressing complications from misplacement that affect up to 30% of procedures. Omeq is a portfolio company of The Trendlines Group Ltd., supported by grants from the Israeli Innovation Authority.

ViAqua Therapeutics announced a successful funding round of $4.3 million aimed at expanding its RNA-particle platform for improving animal health in aquaculture. New investors include S2G Ventures, Thai Union, and Agriline, alongside previous investors like Nutreco and The Trendlines Group. The company aims to address significant challenges in shrimp health caused by viral diseases, which have resulted in 30-40% annual losses in global production. ViAqua's proprietary delivery method and production platform aim to overcome historical obstacles in RNA-based technologies.